SCHEMBL2652375

SCHEMBL2652375

N#Cc1cncnc1-c1cc([N+](=O)[O-])ccc1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 1/20 0.43
GABRG2 P18507 1/20 0.43
GABRB3 P28472 1/20 0.43
GABRA3 P34903 1/20 0.43
VCAM1 P19320 2/20 0.43
ALDH1A1 P00352 5/20 0.40
HIF1A Q16665 1/20 0.40
MEN1 O00255 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C19 P33261 1/20 0.39
KMT2A Q03164 1/20 0.39
LMNA P02545 1/20 0.39
CCNT1 O60563 1/20 0.36
CDK1 P06493 1/20 0.36
CCNB1 P14635 1/20 0.36
CCNA2 P20248 1/20 0.36
CDK2 P24941 1/20 0.36
CDK7 P50613 1/20 0.36
CDK9 P50750 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2649739 0.81 MAPT (0.50) GABRA1GABRG2GABRB3GABRA3VCAM1
SCHEMBL2650896 0.80 VCAM1 (0.44) GABRA1GABRG2GABRB3GABRA3VCAM1
SCHEMBL2652267 0.78 GABRA1 (0.47) GABRA1GABRG2GABRB3GABRA3ALDH1A1
SCHEMBL2652308 0.78 GABRG2 (0.47) GABRA1GABRG2GABRB3GABRA3
SCHEMBL2652003 0.77 VCAM1 (0.44) VCAM1ALDH1A1HIF1AMEN1KMT2A
SCHEMBL2649876 0.73 VCAM1 (0.49) GABRA1GABRG2GABRB3GABRA3VCAM1
SCHEMBL594390 0.73 VCAM1 (0.64) VCAM1ALDH1A1HIF1AMEN1KMT2A
SCHEMBL2649279 0.72 VCAM1 (0.48) GABRA1GABRG2GABRB3GABRA3VCAM1
SCHEMBL2649443 0.72 VCAM1 (0.48) GABRA1GABRG2GABRB3GABRA3VCAM1
SCHEMBL12707398 0.72 VCAM1 (0.42) VCAM1ALDH1A1CYP3A4LMNACCNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1343788-B1 IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME (GB) 2005-11-23 EP disclosed
US-6936608-B2 Imidazo-triazine derivatives as ligands for GABA receptors MERCK SHARP & DOHME LTD. 2005-08-30 US disclosed
US-20040023964-A1 Imidazo-triazine derivatives as ligands for gaba receptors MERCK SHARP & DOHME LTD. (GB) 2004-02-05 US disclosed
EP-1343788-A1 IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LTD. (GB) 2003-09-17 EP disclosed
WO-2002038568-A1 IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LIMITED (GB) 2002-05-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040023964-A1 Imidazo-triazine derivatives as ligands for gaba receptors GABRA2, GABRA5, GABRA1 GABRA1 3/4885GABRG2 14/4885GABRB3 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.